Drug Trial News

RSS

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

22 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

AltheRx reports positive Phase II results of Solabegron for OAB

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520).

21 May 2012

SERVE-HF study on effect of CSA treatment for stable heart failure enrolls 1,000th participant

SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.

From ResMed Corp 21 May 2012

Ipsen, Active Biotech complete half of planned recruitment in tasquinimod phase III study for CRPC

Active Biotech and Ipsen today announced that recruitment to the global, pivotal, randomized, double-blind, placebo-controlled phase III study of tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC) has reached an inclusion of 600 patients, half of the planned accrual.

21 May 2012

Hypertonic saline does not reduce rate of pulmonary exacerbations in young children with CF

Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and colleagues conducted a study to examine if hypertonic saline would reduce the rate of pulmonary exacerbations in children younger than 6 years of age with cystic fibrosis.

21 May 2012

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

21 May 2012

Oxytocin increases brain activations in children and adolescents with ASD

Preliminary results from an ongoing, large-scale study by Yale School of Medicine researchers shows that oxytocin - a naturally occurring substance produced in the brain and throughout the body- increased brain function in regions that are known to process social information in children and adolescents with autism spectrum disorders (ASD).

21 May 2012

Three-drug combo harmful for patients with idiopathic pulmonary fibrosis

A combination of three drugs used worldwide as the standard of care for a serious lung disease puts patients in danger of death or hospitalization, and should not be used together to treat the disease, called idiopathic pulmonary fibrosis, according to the surprising results of a rigorous independent study.

21 May 2012

POZEN presents data from PA32540 Phase 1 gastric acid reduction study at DDW 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time to gastric pH.

21 May 2012

Santarus to present UCERIS Phase III trial data on ulcerative colitis at DDW meeting

Santarus, Inc. today announced that safety and efficacy data from a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study with the investigational drug UCERIS (budesonide) 6 mg tablets will be featured in four poster presentations at the Digestive Disease Week (DDW) Meeting being held at the San Diego Convention Center on May 19 - 22, 2012.

19 May 2012

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific conference.

19 May 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120.

19 May 2012

Data from Purdue Pharma’s Butrans clinical trials to be presented at APS annual meeting

Purdue Pharma L.P. will present an analysis of data from completed clinical trials for Butrans® (buprenorphine) Transdermal System CIII at the American Pain Society's (APS) 31st Annual Scientific Meeting.

19 May 2012

Pfizer announces results from Lyrica clinical studies on fibromyalgia

Pfizer Inc. announced the results of studies on Lyrica (pregabalin) capsules CV presented at the American Pain Society Annual Meeting in Honolulu.

19 May 2012

Data from Almirall, Forest Labs’ aclidinium studies on COPD to be presented at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic Society (ATS) International Conference scheduled May 18 - 23 in San Francisco, CA.

19 May 2012

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that an abstract reporting new data from the BiovaxID Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with the significance of these results to be presented by the NCI at the 2012 American Society of Clinical Oncology Annual Meeting.

19 May 2012

Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase 3 NSCLC trial

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of their investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer.

19 May 2012

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC).

18 May 2012

Drug Trial News

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

AltheRx reports positive Phase II results of Solabegron for OAB

SERVE-HF study on effect of CSA treatment for stable heart failure enrolls 1,000th participant

Ipsen, Active Biotech complete half of planned recruitment in tasquinimod phase III study for CRPC

Hypertonic saline does not reduce rate of pulmonary exacerbations in young children with CF

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Oxytocin increases brain activations in children and adolescents with ASD

Three-drug combo harmful for patients with idiopathic pulmonary fibrosis

POZEN presents data from PA32540 Phase 1 gastric acid reduction study at DDW 2012

Santarus to present UCERIS Phase III trial data on ulcerative colitis at DDW meeting

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Data from Purdue Pharma’s Butrans clinical trials to be presented at APS annual meeting

Pfizer announces results from Lyrica clinical studies on fibromyalgia

Data from Almirall, Forest Labs’ aclidinium studies on COPD to be presented at ATS conference

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase 3 NSCLC trial

Sigmoid provides financial and product development update

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News